EUVIMEDEUVIMED entdecken
Crossref

Oroxin B Resembles Bisoprolol in Attenuating Beta1‐Adrenergic Receptor Autoantibody‐Induced Atrial Remodelling via the PTEN / AKT / mTOR Signalling Pathway

Na Yang, Huaxin Sun, Linqiang Xi, Ling Zhang, Yanmei Lu, Qianhui Wang, Jiaru Cao, Jie Song, Baopeng Tang, Luxiang Shang, Xianhui Zhou iD

Clinical and Experimental Pharmacology and Physiology · 2025

DOI: 10.1111/1440-1681.70011 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Pharmacology and Physiology, 2025. Verfasst von Na Yang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Xinjiang Key Laboratory of Cardiac Electrophysiology and Remodelling, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China. Hauptthemen laut MEDLINE: Receptors, Adrenergic, beta-1, TOR Serine-Threonine Kinases, Atrial Remodeling, Bisoprolol. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Xinjiang Uygur Autonomous Region Postgraduate Research and Innovation Project Grant, China Postdoctoral Science Foundation (2024M751896). Shandong Province Postdoctoral Innovation Projects, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Beta1‐adrenergic receptor autoantibodies (β1‐AAbs) promote atrial remodelling and ultimately lead to the development of atrial fibrillation (AF). Oroxin B is a natural flavonoid glycoside with a variety of biological activities, including anti‐inflammatory and autophagy‐promoting effects, and has therapeutic benefits for a variety of diseases. The aim of this study was to investigate the potential therapeutic role of Oroxin B in the development of β1‐AAb‐induced atrial fibrillation and to elucidate the underlying mechanisms involved. We established a rat model of β1‐AAb‐induced atrial fibrillation via active immunisation. The first stage was divided into three groups: the control group, the β1‐AAb group and the β1‐AAb + bisoprolol group. The second stage was divided into three groups: the control group, the β1‐AAb group and the β1‐AAb + Oroxin B group. Serum levels of β1‐AAbs, atrial tissue levels of cyclic monophosphate (cAMP), atrial electrophysiological parameters, cardiac structure and function, mitochondrial structure, autophagy levels, cardiomyocyte apoptosis and myocardial fibrosis were examined. The results showed that bisoprolol, a β1‐blocker, improved β1‐AAb‐induced atrial electrical remodelling, reduced atrial collagen deposition, ameliorated the increase in LAD and regulated the balance of autophagy and apoptosis in atrial myocytes through the PTEN/AKT/mTOR signalling pathway. Oroxin B, a PTEN agonist, can improve the impairment of autophagy homeostasis and apoptosis in atrial tissue by activating the PTEN/AKT/mTOR signalling pathway, thereby improving atrial structure and electrical remodelling. Moreover, Oroxin B may play a therapeutic role in β1AAb‐induced atrial fibrillation. In conclusion, our results demonstrate the potential therapeutic role of Oroxin B in β1AAb‐induced atrial fibrillation and the underlying mechanisms, suggesting that Oroxin B may be an effective antiarrhythmic medication.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Adrenergic, beta-1TOR Serine-Threonine KinasesAtrial RemodelingBisoprololSignal TransductionProto-Oncogene Proteins c-aktPTEN PhosphohydrolaseAutoantibodiesAnimalsRatsMaleAtrial FibrillationRats, Sprague-DawleyHeart AtriaAutophagyAdrenergic beta-1 Receptor AntagonistsMyocytes, Cardiac

Stichwörter der Autor:innen

Oroxin Bapoptosisatrial fibrillationautophagyβ1‐AAbs

Substanzen

Receptors, Adrenergic, beta-1TOR Serine-Threonine KinasesBisoprololProto-Oncogene Proteins c-aktPTEN PhosphohydrolaseAutoantibodiesmTOR protein, ratPten protein, ratAdrenergic beta-1 Receptor Antagonists

Autor:innen und Institutionen

  • Xinjiang Key Laboratory of Cardiac Electrophysiology and Remodelling, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
  • Department of Pacing and Electrophysiology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
  • Department of Cardiology, the Third People's Hospital of Chengdu, Affiliated Hospital of Southwest Jiaotong University, Chengdu Cardiovascular Disease Research Institute, Chengdu, Sichuan, China.
  • Department of Cardiology, the First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Medicine and Health Key Laboratory of Cardiac Electrophysiology and Arrhyt…
  • Medical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China.

ORCID-Profile: Xianhui Zhou

Förderung

  • Xinjiang Uygur Autonomous Region Postgraduate Research and Innovation Project Grant
  • China Postdoctoral Science Foundation (2024M751896). Shandong Province Postdoctoral Innovation Projects
  • National Natural Science Foundation of China

Zitieren

APA

Yang, N., Sun, H., Xi, L., Zhang, L., Lu, Y., Wang, Q., Cao, J., Song, J., Tang, B., Shang, L., & Zhou, X. (2025). Oroxin B Resembles Bisoprolol in Attenuating Beta1‐Adrenergic Receptor Autoantibody‐Induced Atrial Remodelling via the PTEN / AKT / mTOR Signalling Pathway. Clinical and Experimental Pharmacology and Physiology. https://doi.org/10.1111/1440-1681.70011

Vancouver

Yang N, Sun H, Xi L, Zhang L, Lu Y, Wang Q, et al. Oroxin B Resembles Bisoprolol in Attenuating Beta1‐Adrenergic Receptor Autoantibody‐Induced Atrial Remodelling via the PTEN / AKT / mTOR Signalling Pathway. Clinical and Experimental Pharmacology and Physiology. 2025. doi:10.1111/1440-1681.70011

BibTeX
@article{Yang2025,
  author = {Yang, Na and Sun, Huaxin and Xi, Linqiang and Zhang, Ling and Lu, Yanmei and Wang, Qianhui and Cao, Jiaru and Song, Jie and Tang, Baopeng and Shang, Luxiang and Zhou, Xianhui},
  title = {Oroxin B Resembles Bisoprolol in Attenuating Beta1‐Adrenergic Receptor Autoantibody‐Induced Atrial Remodelling via the PTEN / AKT / mTOR Signalling Pathway},
  journal = {Clinical and Experimental Pharmacology and Physiology},
  year = {2025},
  doi = {10.1111/1440-1681.70011}
}
Kostenlos starten →